MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
September 08, 2024 19:10 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Sept. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative...
The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer
September 04, 2024 08:19 ET
|
Biomerica, Inc.
- 10-Minute At-Home PSA Test for Early Detection of Prostate Cancer - First order already shipped to Saudi Arabia - Prostate Cancer is the Second Most Common Cancer in Men Globally ...
Movember Announces Three Year Partnership With the International Society for Sexual Medicine
September 04, 2024 07:00 ET
|
Movember Canada
Movember is kicking off Prostate Cancer Awareness Month by announcing a new three-year partnership with the International Society for Sexual Medicine.
North America Cancer Biopsy Market Research Report 2024
August 28, 2024 11:10 ET
|
Research and Markets
Dublin, Aug. 28, 2024 (GLOBE NEWSWIRE) -- The "North America Cancer Biopsy Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ...
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
July 30, 2024 07:00 ET
|
Arvinas Inc.
– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2-...
Prostate Health Market Surges Towards USD 83.8 Billion by 2034, Fueled by Advancements in Diagnostic and Treatment Technologies | TMR Report
July 08, 2024 09:58 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research. Inc. , July 08, 2024 (GLOBE NEWSWIRE) -- The prostate health market (Markt für Prostatagesundheit) was projected to attain US$ 31.9...
Lantheus Acquires Global Rights to Life Molecular Imaging’s Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers
June 27, 2024 07:05 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
Curium gibt erste kommerzielle Dosen von PYLCLARI® - 18F-PSMA PET radiopharmazeutikum in Österreich bekannt
June 17, 2024 08:51 ET
|
Curium
Erste Dosen von PYLCLARI® werden Anfang Mai 2024 in Österreich verabreichtPYLCLARI® jetzt auch in Frankreich, Deutschland, Griechenland, Italien und den Niederlanden erhältlich PARIS, June 17, 2024 ...
Curium Continues to Make Strong Progress in European Roll-Out Of PYLCLARI® – 18F-PSMA PET Diagnostics of Patients With Prostate Cancer
June 17, 2024 08:51 ET
|
Curium
First doses of PYLCLARI® administered in Austria in early May 2024PYLCLARI® now available in France, Germany, Greece, Italy, and the Netherlands PARIS, June 17, 2024 (GLOBE NEWSWIRE) -- Curium, a...
Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer
May 30, 2024 03:00 ET
|
Curium
first doses of PYLCLARI in France for prostate cancer patients